

# Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Novartis Pharmaceuticals
<b>Enrollment</b>	123 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Men and women, aged e 18 and d75 years, with a diagnosis of probable or definite myositis according to American College of Rheumatology/European League Against Rheumatism 2017 (ACR/EULAR 2017) criteria
- Participants who had inadequate response to prior therapy
- Diagnosed with active disease
- Participant must meet criteria for severe myositis

### Exclusion (7)

- Any condition during Screening that could prevent a complete washout of medications or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study
  - BMI at Screening of d17 or e40 kg/m2
  - Severe muscle damage at Screening
  - Inadequate organ function
  - Hypersensitivity and/or contraindications to any product (including its ingredients) to be given to the participant as per the study protocol
- ... and 2 more (see full listing online)

## Locations (55 total)

---

University Of Alabama, Birmingham, Alabama, United States  
FL Medical Clinic Orlando Health, Zephyrhills, Florida, United States  
Northwestern University, Chicago, Illinois, United States  
... and 52 more locations